◆ In a key study that the Committee reviewed, sildenafil (Revatio) improved the patients' performance in the 6-minute walk test when compared to patients taking a placebo. In this trial, the quality of life of patients who used sildenafil (Revatio) also improved.
◆ There are no long-term published studies for sildenafil (Revatio) in the treatment of pulmonary arterial hypertension; therefore, the long-term effectiveness of the drug is unknown. There is no evidence that sildenafil decreases mortality.
◆ Overall, the Committee acknowledged that sildenafil (Revatio) appears to have short-term benefits in improving patients' exercise capacity and their quality of life. However, evidence on long-term benefit and safety is lacking. The Committee concluded that sildenafil (Revatio) may be costeffective in selected patients with pulmonary arterial hypertension. It was recommended sildenafil (Revatio) be funded through the EAP for the treatment of pulmonary arterial hypertension with specific criteria.
Background:
Pulmonary arterial hypertension occurs when dangerously high blood pressure builds up in the blood vessels that lead from the heart to the lungs. The small blood vessels in the lungs narrow and their walls thicken, causing the pressure to build and back up. The heart is unable to keep up with the extra work needed to pump blood through the lungs, resulting in right-sided heart failure.
Patients with pulmonary arterial hypertension experience fatigue, dizziness, shortness of breath, chest pain and, eventually, heart failure and death.
The disease can occur on its own due to unknown causes, or as a complication of congenital heart disease, HIV or connective tissue diseases such as scleroderma.
Sildenafil (Revatio) works by blocking an enzyme called phosphodiesterase type 5, relaxing the pulmonary blood vessels, and improving blood flow.
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Executive Officer Decision
Based on the CED's recommendation, the Executive Officer decided to fund sildenafil (Revatio) through the EAP for the treatment of pulmonary arterial hypertension, according to specific criteria.
Status
Funding available through the Ontario Public Drug Programs via the EAP.
CED Recommendation
The CED recommended that sildenafil (Revatio) be funded through the Exceptional Access Program (EAP), according to specific criteria, on the basis that the drug has demonstrated short-term clinical benefits and value for money in selected patients with pulmonary arterial hypertension. -Patient is followed by a specialist in pulmonary arterial hypertension.
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-The approved dose of sildenafil (Revatio) should be limited to 20mg three times daily.
-Consideration will not be given for combinations with any of the following drug therapies: bosentan, epoprostenol, treprostinil.
CEDAC Recommendation:
(http://www.cadth.ca/index.php/ en/cdr/recommendations)
The Canadian Expert Drug Advisory Committee (CEDAC) recommended that sildenafil (Revatio) be listed in the same manner that drug plans list bosentan. 
